{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:57:26Z","timestamp":1793674646991,"version":"4.5.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Research Improvement Program of Anhui Medical University","award":["2021xkjT105"],"award-info":[{"award-number":["2021xkjT105"]}],"id":[{"id":"https:\/\/ror.org\/03xb04968","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Major Project of University Nature Science Research in Anhui Province","award":["2023AH040370"],"award-info":[{"award-number":["2023AH040370"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070629"],"award-info":[{"award-number":["82070629"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270660"],"award-info":[{"award-number":["82270660"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Camptothecin (CPT) is one of the frequently used small chemotherapy drugs for treating hepatocellular carcinoma (HCC), but its clinical application is limited due to severe toxicities and acquired resistance. Combined chemo-gene therapy has been reported to be an effective strategy for counteracting drug resistance while sensitizing cancer cells to cytotoxic agents. Thus, we hypothesized that combining CPT with miR-145 could synergistically suppress tumor proliferation and enhance anti-tumor activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Lactobionic acid (LA) modified lipid nanoparticles (LNPs) were developed to co-deliver CPT and miR-145 into asialoglycoprotein receptors-expressing HCC in vitro and in vivo. We evaluated the synergetic antitumor effect of miR-145 and CPT using CCK8, Western blotting, apoptosis and wound scratch assay in vitro, and the mechanisms underlying the synergetic antitumor effects were further investigated. Tumor inhibitory efficacy, safety evaluation and MRI-visible ability were assessed using diethylnitrosamine (DEN)\u2009+\u2009CCl\n                      <jats:sub>4<\/jats:sub>\n                      -induced HCC mouse model.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The LA modification improved the targeting delivery of cargos to HCC cells and tissues. The LA-CMGL-mediated co-delivery of miR-145 and CPT is more effective on tumor inhibitory than LA-CPT-L or LA-miR-145-L treatment alone, both in vitro and in vivo, with almost no side effects during the treatment period. Mechanistically, miR-145 likely induces apoptosis by targeting SUMO-specific peptidase 1 (SENP1)-mediated hexokinase (HK2) SUMOylation and glycolysis pathways and, in turn, sensitizing the cancer cells to CPT. In vitro and in vivo tests confirmed that the loaded Gd-DOTA served as an effective T1-weighted contrast agent for noninvasive tumor detection as well as real-time monitoring of drug delivery and biodistribution.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The LA-CMGL-mediated co-delivery of miR-145 and CPT displays a synergistic therapy against HCC. The novel MRI-visible, actively targeted chemo-gene co-delivery system for HCC therapy provides a scientific basis and a useful idea for the development of HCC treatment strategies in the future.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-024-03167-9","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:02:33Z","timestamp":1724976153000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Co-delivery of camptothecin and MiR-145 by lipid nanoparticles for MRI-visible targeted therapy of hepatocellular carcinoma"],"prefix":"10.1186","volume":"43","author":[{"given":"Jing","family":"Rong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongtong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiujuan","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saisai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Likang","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,30]]},"reference":[{"key":"3167_CR1","doi-asserted-by":"crossref","unstructured":"Sun Z, Tan Z, Peng C, Yi W: [Corrigendum] HK2 is associated with the Warburg effect and proliferation in liver cancer: Targets for effective therapy with glycyrrhizin. Mol Med Rep 2021;24.","DOI":"10.3892\/mmr.2021.12143"},{"key":"3167_CR2","doi-asserted-by":"crossref","unstructured":"Xiao Y, Liu Y, Yang S, Zhang B, Wang T, Jiang D, Zhang J, Yu D, Zhang N: Sorafenib and gadolinium co-loaded liposomes for drug delivery and MRI-guided HCC treatment. Colloids Surf B Biointerfaces 2016;141:83\u201392.","DOI":"10.1016\/j.colsurfb.2016.01.016"},{"key":"3167_CR3","doi-asserted-by":"crossref","unstructured":"Chen F, Wang H, Zhu J, Zhao R, Xue P, Zhang Q, Bud NM, Qu W, Feng B, Pi J: Camptothecin suppresses NRF2-ARE activity and sensitises hepatocellular carcinoma cells to anticancer drugs. Br J Cancer 2017;117:1495\u20131506.","DOI":"10.1038\/bjc.2017.317"},{"key":"3167_CR4","doi-asserted-by":"crossref","unstructured":"Li Y, Miao Y, Chen M, Chen X, Li F, Zhang X, Gan Y: Stepwise targeting and responsive lipid-coated nanoparticles for enhanced tumor cell sensitivity and hepatocellular carcinoma therapy. Theranostics 2020;10:3722\u20133736.","DOI":"10.7150\/thno.42008"},{"key":"3167_CR5","doi-asserted-by":"crossref","unstructured":"Wang X, Liu G, Chen N, Wu J, Zhang J, Qian Y, Zhang L, Zhou D, Yu Y: Angiopep2-Conjugated Star-Shaped Polyprodrug Amphiphiles for Simultaneous Glioma-Targeting Therapy and MR Imaging. ACS Appl Mater Interfaces 2020;12:12143\u201312154.","DOI":"10.1021\/acsami.0c00509"},{"key":"3167_CR6","doi-asserted-by":"crossref","unstructured":"Wang H, Ellipilli S, Lee WJ, Li X, Vieweger M, Ho YS, Guo P: Multivalent rubber-like RNA nanoparticles for targeted co-delivery of paclitaxel and MiRNA to silence the drug efflux transporter and liver cancer drug resistance. J Control Release 2021;330:173\u2013184.","DOI":"10.1016\/j.jconrel.2020.12.007"},{"key":"3167_CR7","doi-asserted-by":"crossref","unstructured":"Ji D, Wang Q, Zhao Q, Tong H, Yu M, Wang M, Lu T, Jiang C: Co-delivery of miR-29b and germacrone based on cyclic RGD-modified nanoparticles for liver fibrosis therapy. J Nanobiotechnology 2020;18:86.","DOI":"10.1186\/s12951-020-00645-y"},{"key":"3167_CR8","doi-asserted-by":"crossref","unstructured":"Xu F, Liao JZ, Xiang GY, Zhao PX, Ye F, Zhao Q, He XX: MiR-101 and doxorubicin codelivered by liposomes suppressing malignant properties of hepatocellular carcinoma. Cancer Med 2017;6:651\u2013661.","DOI":"10.1002\/cam4.1016"},{"key":"3167_CR9","doi-asserted-by":"crossref","unstructured":"Bao MH, Wong CC: Hypoxia, Metabolic Reprogramming, and Drug Resistance in Liver Cancer. Cells 2021;10.","DOI":"10.3390\/cells10071715"},{"key":"3167_CR10","doi-asserted-by":"crossref","unstructured":"He W, Turkeshi A, Li X, Zhang H: Progress in systemic co-delivery of microRNAs and chemotherapeutics for cancer treatment by using lipid-based nanoparticles. Ther Deliv 2020;11:591\u2013603.","DOI":"10.4155\/tde-2020-0052"},{"key":"3167_CR11","doi-asserted-by":"crossref","unstructured":"Xu W, Hua Y, Deng F, Wang D, Wu Y, Zhang W, Tang J: MiR-145 in cancer therapy resistance and sensitivity: A comprehensive review. Cancer Sci 2020;111:3122\u20133131.","DOI":"10.1111\/cas.14517"},{"key":"3167_CR12","doi-asserted-by":"crossref","unstructured":"Hu C, Liu T, Zhang W, Sun Y, Jiang D, Zhang X, Liu Y, Mao S, Xu Y, Pan J, et al: miR-145 inhibits aerobic glycolysis and cell proliferation of cervical cancer by acting on MYC. FASEB J 2023;37: e22839.","DOI":"10.1096\/fj.202201189RR"},{"key":"3167_CR13","doi-asserted-by":"crossref","unstructured":"Tao J, Ding WF, Che XH, Chen YC, Chen F, Chen XD, Ye XL, Xiong SB: Optimization of a cationic liposome-based gene delivery system for the application of miR-145 in anticancer therapeutics. Int J Mol Med 2016;37:1345\u20131354.","DOI":"10.3892\/ijmm.2016.2530"},{"key":"3167_CR14","doi-asserted-by":"crossref","unstructured":"Qu H, Li X, Chen F, Zhang M, Lu X, Gu Y, Lv M, Lu C: LncRNA PVT1 influences breast cancer cells glycolysis through sponging miR-145-5p. Genes Genomics 2023;45:581\u2013592.","DOI":"10.1007\/s13258-023-01368-8"},{"key":"3167_CR15","doi-asserted-by":"crossref","unstructured":"Obeidat YM, Cheng MH, Catandi G, Carnevale E, Chicco AJ, Chen TW: Design of a multi-sensor platform for integrating extracellular acidification rate with multi-metabolite flux measurement for small biological samples. Biosens Bioelectron 2019;133:39\u201347.","DOI":"10.1016\/j.bios.2019.02.069"},{"key":"3167_CR16","doi-asserted-by":"crossref","unstructured":"Zhao S, Zhang Y, Pei M, Wu L, Li J: miR-145 inhibits mitochondrial function of ovarian cancer by targeting ARL5B. J Ovarian Res 2021;14:8.","DOI":"10.1186\/s13048-020-00762-0"},{"key":"3167_CR17","doi-asserted-by":"crossref","unstructured":"Li W, Chen L, Gu Z, Chen Z, Li H, Cheng Z, Li H, Zou L: Co-delivery of microRNA-150 and quercetin by lipid nanoparticles (LNPs) for the targeted treatment of age-related macular degeneration (AMD). J Control Release 2023;355:358\u2013370.","DOI":"10.1016\/j.jconrel.2023.01.080"},{"key":"3167_CR18","doi-asserted-by":"crossref","unstructured":"Butowska K, Han X, Gong N, El-Mayta R, Haley RM, Xue L, Zhong W, Guo W, Wang K, Mitchell MJ: Doxorubicin-conjugated siRNA lipid nanoparticles for combination cancer therapy. Acta Pharm Sin B 2023;13:1429\u20131437.","DOI":"10.1016\/j.apsb.2022.07.011"},{"key":"3167_CR19","doi-asserted-by":"crossref","unstructured":"Ning Q, Liu YF, Ye PJ, Gao P, Li ZP, Tang SY, He DX, Tang SS, Wei H, Yu CY: Delivery of liver-specific miRNA-122 using a targeted macromolecular prodrug toward synergistic therapy for hepatocellular carcinoma. ACS Appl Mater Interfaces 2019;11:10578\u201310588.","DOI":"10.1021\/acsami.9b00634"},{"key":"3167_CR20","doi-asserted-by":"crossref","unstructured":"Wang L, Hao Y, Li H, Zhao Y, Meng D, Li D, Shi J, Zhang H, Zhang Z, Zhang Y: Co-delivery of doxorubicin and siRNA for glioma therapy by a brain targeting system: angiopep-2-modified poly (lactic-co-glycolic acid) nanoparticles. J Drug Target 2015;23:832\u2013846.","DOI":"10.3109\/1061186X.2015.1025077"},{"key":"3167_CR21","doi-asserted-by":"crossref","unstructured":"Li T, Liu Z, Fu X, Chen Y, Zhu S, Zhang J: Co-delivery of Interleukin-12 and doxorubicin loaded Nano-delivery system for enhanced immunotherapy with polarization toward M1-type Macrophages. Eur J Pharm Biopharm 2022;177:175\u2013183.","DOI":"10.1016\/j.ejpb.2022.07.002"},{"key":"3167_CR22","doi-asserted-by":"crossref","unstructured":"Sabnis S, Kumarasinghe ES, Salerno T, Mihai C, Ketova T, Senn JJ, Lynn A, Bulychev A, McFadyen I, Chan J, et al: A novel amino lipid series for mRNA delivery: Improved endosomal escape and sustained pharmacology and safety in non-human primates. Mol Ther 2018;26:1509\u20131519.","DOI":"10.1016\/j.ymthe.2018.03.010"},{"key":"3167_CR23","doi-asserted-by":"crossref","unstructured":"Han X, Gong N, Xue L, Billingsley MM, El-Mayta R, Shepherd SJ, Alameh MG, Weissman D, Mitchell MJ: Ligand-tethered lipid nanoparticles for targeted RNA delivery to treat liver fibrosis. Nat Commun 2023;14:75.","DOI":"10.1038\/s41467-022-35637-z"},{"key":"3167_CR24","doi-asserted-by":"crossref","unstructured":"Zhang J, Shen H, Xu J, Liu L, Tan J, Li M, Xu N, Luo S, Wang J, Yang F, et al: Liver-targeted sirna lipid nanoparticles treat hepatic cirrhosis by dual antifibrotic and anti-inflammatory activities. ACS Nano 2020;14:6305\u20136322.","DOI":"10.1021\/acsnano.0c02633"},{"key":"3167_CR25","doi-asserted-by":"crossref","unstructured":"Cheng Q, Wei T, Farbiak L, Johnson LT, Dilliard SA, Siegwart DJ: Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. Nat Nanotechnol 2020;15:313\u2013320.","DOI":"10.1038\/s41565-020-0669-6"},{"key":"3167_CR26","doi-asserted-by":"crossref","unstructured":"Dilliard SA, Siegwart DJ: Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs. Nat Rev Mater 2023;8:282\u2013300.","DOI":"10.1038\/s41578-022-00529-7"},{"key":"3167_CR27","doi-asserted-by":"crossref","unstructured":"Akinc A, Maier MA, Manoharan M, Fitzgerald K, Jayaraman M, Barros S, Ansell S, Du X, Hope MJ, Madden TD, et al: The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nat Nanotechnol 2019;14:1084\u20131087.","DOI":"10.1038\/s41565-019-0591-y"},{"key":"3167_CR28","doi-asserted-by":"crossref","unstructured":"Wang X, Liu S, Sun Y, Yu X, Lee SM, Cheng Q, Wei T, Gong J, Robinson J, Zhang D, et al: Preparation of selective organ-targeting (SORT) lipid nanoparticles (LNPs) using multiple technical methods for tissue-specific mRNA delivery. Nat Protoc 2023;18:265\u2013291.","DOI":"10.1038\/s41596-022-00755-x"},{"key":"3167_CR29","doi-asserted-by":"crossref","unstructured":"Fei Q, Shalosky EM, Barnes R, Shukla VC, Xu S, Ballinger MN, Farkas L, Lee RJ, Ghadiali SN, Englert JA: Macrophage-targeted lipid nanoparticle delivery of microRNA-146a to mitigate hemorrhagic shock-induced acute respiratory distress syndrome. ACS Nano 2023;17:16539\u201316552.","DOI":"10.1021\/acsnano.3c01814"},{"key":"3167_CR30","doi-asserted-by":"crossref","unstructured":"Zhou T, Liang X, Wang P, Hu Y, Qi Y, Jin Y, Du Y, Fang C, Tian J: A hepatocellular carcinoma targeting nanostrategy with hypoxia-ameliorating and photothermal abilities that, combined with immunotherapy, inhibits metastasis and recurrence. ACS Nano 2020;14:12679\u201312696.","DOI":"10.1021\/acsnano.0c01453"},{"key":"3167_CR31","doi-asserted-by":"crossref","unstructured":"Ren L, Chen S, Li H, Zhang Z, Ye C, Liu M, Zhou X: MRI-visible liposome nanovehicles for potential tumor-targeted delivery of multimodal therapies. Nanoscale 2015;7:12843\u201312850.","DOI":"10.1039\/C5NR02144H"},{"key":"3167_CR32","doi-asserted-by":"crossref","unstructured":"Xie X, Chen Y, Chen Z, Feng Y, Wang J, Li T, Li S, Qin X, Wu C, Zheng C, et al: Polymeric hybrid nanomicelles for cancer theranostics: An efficient and precise anticancer strategy for the codelivery of doxorubicin\/mir-34a and magnetic resonance imaging. ACS Appl Mater Interfaces 2019;11:43865\u201343878.","DOI":"10.1021\/acsami.9b14908"},{"key":"3167_CR33","doi-asserted-by":"crossref","unstructured":"Andreozzi E, Wang P, Valenzuela A, Tu C, Gorin F, Dhenain M, Louie A: Size-stable solid lipid nanoparticles loaded with Gd-DOTA for magnetic resonance imaging. Bioconjug Chem 2013;24:1455\u20131467.","DOI":"10.1021\/bc300605f"},{"key":"3167_CR34","doi-asserted-by":"crossref","unstructured":"Li X, Qian Y, Liu T, Hu X, Zhang G, You Y, Liu S: Amphiphilic multiarm star block copolymer-based multifunctional unimolecular micelles for cancer targeted drug delivery and MR imaging. Biomaterials 2011;32:6595\u20136605.","DOI":"10.1016\/j.biomaterials.2011.05.049"},{"key":"3167_CR35","doi-asserted-by":"crossref","unstructured":"Yao W, Liu C, Wang N, Zhou H, Chen H, Qiao W: An MRI-guided targeting dual-responsive drug delivery system for liver cancer therapy. J Colloid Interface Sci 2021;603:783\u2013798.","DOI":"10.1016\/j.jcis.2021.06.151"},{"key":"3167_CR36","doi-asserted-by":"crossref","unstructured":"Zhang L, Zhang M, Zhou L, Han Q, Chen X, Li S, Li L, Su Z, Wang C: Dual drug delivery and sequential release by amphiphilic Janus nanoparticles for liver cancer theranostics. Biomaterials 2018;181:113\u2013125.","DOI":"10.1016\/j.biomaterials.2018.07.060"},{"key":"3167_CR37","doi-asserted-by":"crossref","unstructured":"Qi C, Wang D, Gong X, Zhou Q, Yue X, Li C, Li Z, Tian G, Zhang B, Wang Q, et al: Co-Delivery of Curcumin and Capsaicin by Dual-Targeting Liposomes for Inhibition of aHSC-Induced Drug Resistance and Metastasis. ACS Appl Mater Interfaces 2021;13:16019\u201316035.","DOI":"10.1021\/acsami.0c23137"},{"key":"3167_CR38","doi-asserted-by":"crossref","unstructured":"Zou Y, Song Y, Yang W, Meng F, Liu H, Zhong Z: Galactose-installed photo-crosslinked pH-sensitive degradable micelles for active targeting chemotherapy of hepatocellular carcinoma in mice. J Control Release 2014;193:154\u2013161.","DOI":"10.1016\/j.jconrel.2014.05.016"},{"key":"3167_CR39","doi-asserted-by":"crossref","unstructured":"Wei X, Yang D, Xing Z, Cai J, Wang L, Zhao C, Wei X, Jiang M, Sun H, Zhou L, et al: Hepatocyte-targeted delivery using oleanolic acid-loaded liposomes for enhanced hepatocellular carcinoma therapy. Biomater Sci 2023;11:3952\u20133964.","DOI":"10.1039\/D3BM00261F"},{"key":"3167_CR40","doi-asserted-by":"crossref","unstructured":"Wang Q, Tian Y, Liu L, Chen C, Zhang W, Wang L, Guo Q, Ding L, Fu H, Song H, et al: Precise targeting therapy of orthotopic gastric carcinoma by siRNA and chemotherapeutic drug codelivered in ph-sensitive nano platform. Adv Healthc Mater 2021;10: e2100966.","DOI":"10.1002\/adhm.202100966"},{"key":"3167_CR41","doi-asserted-by":"crossref","unstructured":"Andersson TB, Kanebratt KP, Kenna JG: The HepaRG cell line: a unique in vitro tool for understanding drug metabolism and toxicology in human. Expert Opin Drug Metab Toxicol 2012;8:909\u2013920.","DOI":"10.1517\/17425255.2012.685159"},{"key":"3167_CR42","doi-asserted-by":"crossref","unstructured":"Brand M, Bommeli EB, R\u00fctimann M, Lindenmann U, Riedl R: Discovery of a Dual SENP1 and SENP2 Inhibitor. Int J Mol Sci 2022;23.","DOI":"10.3390\/ijms232012085"},{"key":"3167_CR43","doi-asserted-by":"crossref","unstructured":"Fu Y, Mackowiak B, Feng D, Lu H, Guan Y, Lehner T, Pan H, Wang XW, He Y, Gao B: MicroRNA-223 attenuates hepatocarcinogenesis by blocking hypoxia-driven angiogenesis and immunosuppression. Gut 2023;72:1942\u20131958.","DOI":"10.1136\/gutjnl-2022-327924"},{"key":"3167_CR44","doi-asserted-by":"crossref","unstructured":"Zhang D, Wang G, Yu X, Wei T, Farbiak L, Johnson LT, Taylor AM, Xu J, Hong Y, Zhu H, Siegwart DJ: Enhancing CRISPR\/Cas gene editing through modulating cellular mechanical properties for cancer therapy. Nat Nanotechnol 2022;17:777\u2013787.","DOI":"10.1038\/s41565-022-01122-3"},{"key":"3167_CR45","doi-asserted-by":"crossref","unstructured":"DeWaal D, Nogueira V, Terry AR, Patra KC, Jeon SM, Guzman G, Au J, Long CP, Antoniewicz MR, Hay N: Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin. Nat Commun 2018;9:446.","DOI":"10.1038\/s41467-017-02733-4"},{"key":"3167_CR46","doi-asserted-by":"crossref","unstructured":"Liao W, Du J, Wang Z, Feng Q, Liao M, Liu H, Yuan K, Zeng Y: The role and mechanism of noncoding RNAs in regulation of metabolic reprogramming in hepatocellular carcinoma. Int J Cancer 2022;151:337\u2013347.","DOI":"10.1002\/ijc.34040"},{"key":"3167_CR47","doi-asserted-by":"crossref","unstructured":"Zheng X, Pan Y, Yang G, Liu Y, Zou J, Zhao H, Yin G, Wu Y, Li X, Wei Z, et al: Kaempferol impairs aerobic glycolysis against melanoma metastasis via inhibiting the mitochondrial binding of HK2 and VDAC1. Eur J Pharmacol 2022;931:175226.","DOI":"10.1016\/j.ejphar.2022.175226"},{"key":"3167_CR48","doi-asserted-by":"crossref","unstructured":"Shangguan X, He J, Ma Z, Zhang W, Ji Y, Shen K, Yue Z, Li W, Xin Z, Zheng Q, et al: SUMOylation controls the binding of hexokinase 2 to mitochondria and protects against prostate cancer tumorigenesis. Nat Commun 2021;12:1812.","DOI":"10.1038\/s41467-021-22163-7"},{"key":"3167_CR49","doi-asserted-by":"crossref","unstructured":"Uehara T, Ainslie GR, Kutanzi K, Pogribny IP, Muskhelishvili L, Izawa T, Yamate J, Kosyk O, Shymonyak S, Bradford BU, et al: Molecular mechanisms of fibrosis-associated promotion of liver carcinogenesis. Toxicol Sci 2013;132:53\u201363.","DOI":"10.1093\/toxsci\/kfs342"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-024-03167-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-024-03167-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-024-03167-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:08:57Z","timestamp":1724976537000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-024-03167-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,30]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3167"],"URL":"https:\/\/doi.org\/10.1186\/s13046-024-03167-9","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,30]]},"assertion":[{"value":"3 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animal protocols were approved by Animal Experiment Ethics Review of Anhui Medical University (NO: LLSC20221110), which are consistent with AAALAS guidelines. Liver tumor tissues and non-tumor tissues were procured from the tissue biorepository through the department of Pathology, the first affiliated hospital of Anhui Medical University (AHMU). Following guidelines described by the Declaration of Helsinki, Institutional Review Board approval (NO: 2023\u2009\u2212\u2009467) from the first affiliated hospital of AHMU was obtained for experimental use of specimens.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All authors agreed to submit this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing financial interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"247"}}